Bristol Myers wins EU backing to expand label for anemia therapy

Jan. 27, 2023 7:19 AM ETBristol-Myers Squibb Company (BMY), MRKBy: Dulan Lokuwithana, SA News Editor

Stock Markets Open One Day After Steep Drop Over Apple"s Revised Forecast

Drew Angerer/Getty Images News

  • The European Medicines Agency (EMA) announced Friday that an independent advisory panel of the regulator recommended expanding the marketing authorization for anemia therapy Reblozyl, as requested by Bristol Myers Squibb (NYSE:BMY).
  • In 2020, the EU approved

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.